Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multi-center study
References (53)
Double-blind study of ipratropium bromide, a new anticholinergic bronchodilator
J Allergy Clin Immunol
(1977)- et al.
The short-term bronchodilator effects of fenoterol and ipratropium in asthma
J Allergy Clin Immunol
(1982) - et al.
Bronchodilator action of the anticholinergic drug, ipratropium bromide (SCH 1000), as an aerosol in chronic bronchitis and asthma
Chest
(1977) - et al.
The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis
Chest
(1982) - et al.
The effect of atropine inhalation in “irreversible” chronic bronchitis
Chest
(1980) - et al.
Comparative bronchodilator responses to atropine and terbutaline in asthma and chronic bronchitis
Chest
(1977) - et al.
Effect of inhaled atropine or metaproterenol in patients with chronic airway obstruction and therapeutic serum theophylline levels
Chest
(1984) - et al.
The effect of sequential inhalations of metaproterenol aerosol in asthma
J Allergy Clin Immunol
(1980) - et al.
Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation
J Allergy Clin Immunol
(1977) The development of drug tolerance to beta2 adrenergic agents
Chest
(1978)
Evaluation of oral fenoterol in chronic asthmatic patients
Chest
Efficacy and side effects of fenoterol compared with isoproterenol administered by metered dose inhaler in asthma
Chest
Lack of bronchial betaadrenoceptor resistance in asthmatics during long-term treatment with terbutaline
J Allergy Clin Immunol
Cardiopulmonary effects of long-term bronchodilator administration
J Allergy Clin Immunol
Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol
J Allergy Clin Immunol
Anticholinergic, antimuscarinic bronchodilators
Am Rev Respir Dis
Therapeutic aerosols 2-drugs available by the inhaled route (editorial)
Thorax
The effect of Sch 1000 MDI on the mucociliary clearance and lung function of healthy volunteers (abstr)
Postgrad Med J
Sputum rheology following treatment with Sch 1000 MDI and orciprenaline MDI (abstr)
Postgrad Med J
Quantitative and selective bronchial clearance studies using 99mTc-sulfate particles
Scand J Respir Dis
Effect of aerosol ipratropium bromide (Sch 1000) on sputum viscosity and volume in chronic bronchitis (letter)
Br J Clin Pharmacol
Sputum viscoelasticity following administration of SCH 1000 MDI (abstr)
Postgrad Med J
Ipratropiumbromid in der kontrollierten Klinischen Prufung
Bronchodilator action of two different doses of ipratropium bromide (Sch 1000) compared with fenoterol and placebo
Curr Ther Res
Anticholinergika als Bronchodilatatoren
Arzneimittelforsch
A comparative study of atropine sulfate and isoproterenol hydrochloride in chronic bronchitis
Am Rev Respir Dis
Cited by (135)
Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline
2015, ChestCitation Excerpt :There was a small increase in prebronchodilator FVC and a postbronchodilator increase in the FVC area under the curve over 8 h, and this approached statistical significance. These data suggest that the beneficial effects of a short-acting muscarinic antagonist over short-acting β2-agonist are small in terms of lung function.154–160 There was no study evaluating exacerbation as a primary end point.
Anticholinergic Therapies
2014, Middleton's Allergy: Principles and Practice: Eighth EditionManagement of respiratory diseases
2013, Tidy's Physiotherapy: Fifteenth EditionAcute Exacerbations of Chronic Obstructive Pulmonary Disease in the Emergency Department
2012, Emergency Medicine Clinics of North AmericaCitation Excerpt :There is some thought that anticholinergic agents may be superior to β2-agonists to treat the reversible component of COPD based on disease pathophysiology and on anticholinergic mechanism of action. This may be the case in stable COPD.82 In AECOPD, the evidence does not favor one over the other.
Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease
2023, Naunyn-Schmiedeberg's Archives of PharmacologyClinical Testing of Aerosol Drugs
2018, Respiratory Drug Delivery
- ∗
Authors' affiliations are listed at the end of this article.